Overview

• A multicenter phase 3 trial is enrolling more than 740 patients across 28 sites in the United States, Europe and Israel to confirm the benefits of combining TTFields with chemotherapy and pembrolizumab.
• In the phase 2 2-THE-TOP trial, newly diagnosed glioblastoma patients receiving TTFields alongside temozolomide and pembrolizumab experienced a 70% increase in overall survival versus historical controls.
• TTFields use low-intensity, alternating electric fields delivered via scalp electrodes to disrupt cancer cell division and enhance T cell infiltration into tumors.
• Patients with large, unresected tumors demonstrated the strongest immune activation and extended survival when treated with the three-pronged regimen.
• Glioblastoma typically carries a median survival of eight months, and this combined approach offers a potential new standard for a cancer with historically limited treatment options.